Publications by authors named "Daniel Shu"

Claim this Profile
C
Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.
Eric S Christenson, Won Jin Ho, Daniel Shu, Jennifer N Durham, Madelena Brancati

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Immunotherapy Promotes the Formation of Mature Tertiary Lymphoid Structures in a Remodeled Pancreatic Tumor Microenvironment.
Dimitrios N Sidiropoulos, Sarah M Shin, Meredith Wetzel, Alexander A Girgis, Daniel Bergman, Daniel Shu

Cancer Immunol Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNAJ-PKAc induces metabolic rewiring and enhanced glutamine flux in fibrolamellar HCC.
Zeal Kamdar, Ethan Neumann, Kathryn Howe, Donald Long, Waqar Arif, Daniel H Shu

J Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.
Eric S Christenson, Won Jin Ho, Daniel Shu, Jennifer N Durham, Madelena Brancati

Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
More than the sum: How vascular endothelial growth factor inhibition unlocks the full potential of immune checkpoint blockade.
Daniel H Shu, Mark Yarchoan

Immunity· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors.
Chester Kao, Soren Charmsaz, Hua-Ling Tsai, Khaled Aziz, Daniel H Shu

Nat Commun· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging.
Marina Baretti, Soumya Shekhar, Vaibhav Sahai, Daniel Shu, Kathryn Howe

Hepatol Commun· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.
Antonio D'Alessio, Bernardo Stefanini, Julia Blanter, Benjamin Adegbite, Fionnuala Crowley, Daniel H Shu

Lancet Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma.
Daniel H Shu, Won Jin Ho, Luciane T Kagohara, Alexander Girgis, Sarah M Shin

Nat Immunol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maturation of Tertiary Lymphoid Structures.
Daniel H Shu, Dimitrios N Sidiropoulos

Methods Mol Biol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic responders.
Dimitrios N Sidiropoulos, Sarah M Shin, Meredith Wetzel, Alexander A Girgis, Daniel Bergman, Daniel H Shu

bioRxiv· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
Mark Yarchoan, Edward J Gane, Thomas U Marron, Renzo Perales-Linares, Jian Yan, Daniel H Shu

Nat Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade.
Daniel H Shu, Won Jin Ho, Luciane T Kagohara, Alexander Girgis, Sarah M Shin

bioRxiv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.
Stephanie L Alden, Mir Lim, Chester Kao, Daniel Shu, Amit G Singal

Cancer Res Commun· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profiling of syngeneic mouse HCC tumor models as a framework to understand anti-PD-1 sensitive tumor microenvironments.
Daniel J Zabransky, Ludmila Danilova, James M Leatherman, Tamara Y Lopez-Vidal, Jessica Sanchez, Daniel Shu

Hepatology· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.
Olivier Godeaux, Martina Kovac, Daniel Shu, Katrijn Grupping, Laura Campora

Hum Vaccin Immunother· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prion-like Aggregation of Mitochondrial Antiviral Signaling Protein in Lupus Patients Is Associated With Increased Levels of Type I Interferon.
Wen-Hai Shao, Daniel H Shu, Yuxuan Zhen, Brendan Hilliard, Stephen O Priest

Arthritis Rheumatol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of a 6-week course of oseltamivir prophylaxis for seasonal influenza in children.
Keith Reisinger, Daniel Shu, Lisa Cupelli, Isaac Marcadis, Regina Dutkowski

Influenza Other Respir Viruses· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis